澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - everolimus, quantity: 1 mg - tablet, uncoated - excipient ingredients: lactose; acetone; butylated hydroxytoluene; magnesium stearate; ethanol absolute; lactose monohydrate; crospovidone; hypromellose - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - everolimus, quantity: 0.75 mg - tablet, uncoated - excipient ingredients: hypromellose; butylated hydroxytoluene; ethanol absolute; acetone; crospovidone; lactose; magnesium stearate; lactose monohydrate - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - everolimus, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: lactose; ethanol absolute; magnesium stearate; lactose monohydrate; hypromellose; crospovidone; acetone; butylated hydroxytoluene - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).

美国 - 英文 - NLM (National Library of Medicine)

natco pharma limited - everolimus (unii: 9hw64q8g6g) (everolimus - unii:9hw64q8g6g) - everolimus is indicated for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant [see clinical studies (14.1)]. everolimus is to be administered in combination with basiliximab induction and concurrently with reduced doses of cyclosporine and with corticosteroids. therapeutic drug monitoring (tdm) of everolimus and cyclosporine is recommended for all patients receiving these products [see dosage and administration (2.2, 2.3)] . everolimus is indicated for the prophylaxis of allograft rejection in adult patients receiving a liver transplant. everolimus is to be administered no earlier than 30 days post-transplant concurrently in combination with reduced doses of tacrolimus and with corticosteroids [see warnings and precautions (5.5), clinical studies (14.2)]. tdm of everolimus and tacrolimus is recommended for all patients receiving these products [see dosage and administration (2.3, 2.5)]. the safety and efficacy of everolimus has not been estab

美国 - 英文 - NLM (National Library of Medicine)

par pharmaceutical, inc. - everolimus (unii: 9hw64q8g6g) (everolimus - unii:9hw64q8g6g) - everolimus tablets are indicated for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant [see clinical studies (14.1) ] everolimus is to be administered in combination with basiliximab induction and concurrently with reduced doses of cyclosporine and with corticosteroids. tdm of everolimus and cyclosporine is recommended for all patients receiving these products. [see dosage and administration (2.2, 2.3) ] everolimus is indicated for the prophylaxis of allograft rejection in adult patients receiving a liver transplant. everolimus is to be administered no earlier than 30 days post-transplant concurrently in combination with reduced doses of tacrolimus and with corticosteroids [see warnings and precautions (5.5) and clinical studies (14.2) ]. therapeutic drug monitoring (tdm) of everolimus and tacrolimus is recommended for all patients receiving these products. [see dosage and administration (2.3, 2.5) ] the safety and efficacy of everolimus has no

美国 - 英文 - NLM (National Library of Medicine)

par pharmaceutical, inc. - everolimus (unii: 9hw64q8g6g) (everolimus - unii:9hw64q8g6g) - everolimus tablets are indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, her2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. everolimus tablets are indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (pnet) with unresectable, locally advanced or metastatic disease. limitations of use : everolimus tablets are not indicated for the treatment of patients with functional carcinoid tumors [see clinical studies (14.2)]. everolimus tablets are indicated for the treatment of adult patients with advanced rcc after failure of treatment with sunitinib or sorafenib. everolimus tablets are indicated for the treatment of adult patients with renal angiomyolipoma and tsc, not requiring immediate surgery. everolimus tablets are indicated in adult and pediatric patients aged 1 year and older with tsc for the treatment of sega that requires therapeutic intervention bu

美国 - 英文 - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - everolimus (unii: 9hw64q8g6g) (everolimus - unii:9hw64q8g6g) - everolimus is indicated for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant [see clinical studies (14.1)] . everolimus is to be administered in combination with basiliximab induction and concurrently with reduced doses of cyclosporine and with corticosteroids. therapeutic drug monitoring (tdm) of everolimus and cyclosporine is recommended for all patients receiving these products [see dosage and administration (2.2 and 2.3)] . everolimus is indicated for the prophylaxis of allograft rejection in adult patients receiving a liver transplant. everolimus is to be administered no earlier than 30 days posttransplant concurrently in combination with reduced doses of tacrolimus and with corticosteroids [see warnings and precautions (5.5) and clinical studies (14.2)] . tdm of everolimus and tacrolimus is recommended for all patients receiving these products [see dosage and administration (2.3, 2.5)] . the safety and efficacy of everolimus has not been

美国 - 英文 - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - everolimus (unii: 9hw64q8g6g) (everolimus - unii:9hw64q8g6g) - everolimus tablets are indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, her2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. everolimus tablets are indicated for the treatment of adult patients with progressive, well-differentiated, non-functional net of gastrointestinal (gi) or lung origin with unresectable, locally advanced or metastatic disease. limitations of use : everolimus tablets are not indicated for the treatment of patients with functional carcinoid tumors [see clinical studies (14.2)]. everolimus tablets are indicated for the treatment of adult patients with renal angiomyolipoma and tsc, not requiring immediate surgery. everolimus tablets are indicated in adult and pediatric patients aged 1 year and older with tsc for the treatment of sega that requires therapeutic intervention but cannot be curatively resected. everolimus is contraindicated in patients with clinically significant hypersen

美国 - 英文 - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - everolimus (unii: 9hw64q8g6g) (everolimus - unii:9hw64q8g6g) - everolimus tablets are indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, her2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. everolimus tablets are indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (pnet) with unresectable, locally advanced or metastatic disease. everolimus tablets are indicated for the treatment of adult patients with progressive, well-differentiated, non-functional net of gastrointestinal (gi) or lung origin with unresectable, locally advanced or metastatic disease. limitations of use: everolimus tablets are not indicated for the treatment of patients with functional carcinoid tumors [see clinical studies (14.2)]. everolimus tablets are indicated for the treatment of adult patients with advanced rcc after failure of treatment with sunitinib or sorafenib. everolimus tablets are indicated for the treatment of adult patients with

美国 - 英文 - NLM (National Library of Medicine)

natco pharma limited - everolimus (unii: 9hw64q8g6g) (everolimus - unii:9hw64q8g6g) - everolimus tablets are indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, her2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. everolimus tablets are indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (pnet) with unresectable, locally advanced or metastatic disease. everolimus tablets are indicated for the treatment of adult patients with progressive, well-differentiated, non-functional net of gastrointestinal (gi) or lung origin with unresectable, locally advanced or metastatic disease. limitations of use:  everolimus tablets are not indicated for the treatment of patients with functional carcinoid tumors [see clinical studies (14.2)] . everolimus tablets are indicated for the treatment of adult patients with advanced rcc after failure of treatment with sunitinib or sorafenib. everolimus tablets are indicated for the treatment of adult patients wi